Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
Arcutis Biotherapeutics (ARQT) Stock Price & Analysis
655 Followers
ARQT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.76 - $13.17
Previous Close$9.56
Volume1.96M
Average Volume (3M)3.02M
Market Cap
$1.11B
Enterprise Value$909.58M
Total Cash (Recent Filing)$403.87M
Total Debt (Recent Filing)$206.74M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 01, 2024EPS Estimate
-$0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.92
Shares Outstanding115,764,164
10 Day Avg. Volume2,998,933
30 Day Avg. Volume3,022,335
Standard Deviation0.28
R-Squared0.05
Alpha0.00564
Financial Highlights & Ratios
Price to Book (P/B)11.95
Price to Sales (P/S)19.83
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.55
Enterprise Value/Gross Profit16.65
Enterprise Value/Ebitda-5.01
Forecast
1Y Price Target
$17.00Price Target Upside82.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arcutis Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Long-term EfficacyArcutis presented long-term data out to 56 weeks for roflumilast cream 0.15% that demonstrated further improvement in efficacy, without new safety signals, in subjects ages 6 years and older with atopic dermatitis.
Medicaid CoverageA recent win earning Texas State Medicaid coverage for both Zoryve Cream and Zoryve Foam, which should come online very shortly.
Prescription GrowthZoryve Foam posted 4,527 TRxs, up 19.2% from 3,799 TRxs in the prior week.
Bears Say
Financial PerformanceZoryve Foam posted 3,799 TRxs, down 10.4% from the prior week's 4,238 TRxs.
Legal RisksArcutis' lawsuit should trigger a 30-month stay which could prevent FDA final approval of a generic Zoryve Cream until October 26, 2026.
Market PerformanceARQT experienced a significant sell-off as a result of weak Zoryve Foam w/w growth seen in the prior two weeks.
---
Ownership Overview
15.42% Insiders
26.24% Mutual Funds
14.29% Other Institutional Investors
44.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $1.76 and its highest was $13.17 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Currently, no data Available
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 29 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on May 14, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.685 by $0.365.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -$0.52.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 115,764,170 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.685. Following the earnings report the stock price went up 13.653%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Among the largest hedge funds holding Arcutis Biotherapeutics’s share is Gilder Gagnon Howe & Co LLC.. It holds Arcutis Biotherapeutics’s shares valued at 42M.
---
Arcutis Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (82.80% Upside)
$17.00 (82.80% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 6.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $934.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.31%
12-Months-Change
Fundamentals
Return on Equity
-119.24%
Trailing 12-Months
Asset Growth
26.11%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
---
ARQT Company Deck
---
ARQT Earnings Call
Q1 2024
0:00 / 0:00
---
ARQT Stock 12 Month Forecast
Average Price Target
$17.00
▲(82.80% Upside)
Technical Analysis
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
+13.85%
reiterated a buy rating 4 months ago
Copying Vikram Purohit's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of +13.85% per trade.
---